Therefore, the management of NAFLD induced by elevated cholesterol levels may include upregulating LDLR accumulation or suppressing proprotein convertase subtilisin/kexin9 (PCSK9)-mediated LDLR degradation to enhance LDLR levels. The gene discussed is PCSK9; the disease is metabolic dysfunction-associated steatotic liver disease.